IO Biotech has filed for bankruptcy in U.S. court after reviewing strategic alternatives, ceasing operations as its assets were placed under a court-appointed trustee; all employees were terminated and the full board resigned. The collapse follows FDA advice against filing for approval after a Phase III melanoma study of Cylembio plus Keytruda (pembrolizumab) delivered an underwhelming progression-free survival benefit.

Why It Matters To Oncology

• The bankruptcy underscores the regulatory and clinical bar for therapeutic cancer vaccines—especially when paired with PD-1 backbones like Keytruda.

• A Phase III “underwhelming” PFS signal can be decisive for capital access and partner confidence, even in a hot modality like immuno-oncology combinations.

• For drug discovery teams, it’s a reminder that platform promise doesn’t substitute for clear, approvable endpoints in late-stage trials.

The Financials

• IO Biotech filed for bankruptcy and placed assets with a court-appointed trustee, marking a complete cessation of operations.

• All employees were terminated without cause, including CEO Mai-Britt Zocca and CFO Amy Sullivan.

• All six board members resigned in conjunction with the filing.

What They're Saying

• The company said the decision followed a review of all available strategic alternatives.

• Trouble accelerated after the FDA advised against submitting a marketing application for Cylembio + Keytruda in melanoma due to an underwhelming PFS benefit.

• The FDA feedback previously triggered layoffs of nearly half the workforce.

What's Next

• The trustee process will determine whether IO Biotech’s assets are sold, licensed, or otherwise restructured.

• Competitors and potential acquirers will watch for any salvageable clinical/regulatory learnings from the Phase III melanoma program and combo strategy with Keytruda.

• Clinicians should expect limited near-term program continuity absent a buyer willing to fund additional studies.